Preoperative MRI scans were co-registered with the postoperative MRI/CT scan, followed by normalization to standard MNI152 space (https://www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009). …
This process involves the localization of the electrodes in each patient’s brain and the estimation of the volume of activated tissue (VAT) based on the stimulation parameters associated with …
(A) Patients were divided in three main groups according to age: pediatric population (≤17years, 11 out of 33), young adults (18–30years, 14 out of 33) and older adults (31–52years, 8 out of 33). (B)…
(A) The area of stimulation associated with greater symptomatic improvement (red) was located in the more posterior-inferior-lateral region of the posterior hypothalamic area (from left to right: …
Note that a small portion of the map overlaps with the most superior part of the red nucleus, and no overlap with the subthalamic nucleus is observed. The labels for the Subthalamic nucleus and red …
Note the striking similarity between maps, with the location and values of the peak corresponding to the most efficacious area for maximal symptom alleviation remaining unaltered, and only a few …
(A) Magnetic resonance imaging (MRI) in the sagittal plane showing the fiber density of streamlines connected to the volumes of activated tissue (VATs) associated with significantly greater …
Magnetic Resonance Imaging (MRI) in the sagittal (A), coronal (B) and axial (C) planes showing the fiber density of streamlines (pink scale) connected to the volumes of activated tissue (VATs) …
Magnetic resonance imaging (MRI) in the axial plane showing areas found to have a positive (warm colors) or a negative (cold colors) correlation between clinical outcome and functional connectivity. …
Magnetic resonance imaging (MRI) in the axial plane (A) and coronal plane (B) showing areas found to have a positive correlation between clinical outcome and functional connectivity (warm colors) or …
(A) Location of the peak extracted for each area found to have significant functional connectivity with the volume of activated tissue Illustrated in the coronal plane in MNI152 standard-space (http:…
Case | Sex | Age range | Improvement (%) | Laterality | DBS System | Stimulation Settings | |
---|---|---|---|---|---|---|---|
Right | Left | ||||||
1 | M | 31–52 | 100 | Bilateral | Medtronic 3387 | 1.8V; 180Hz; 60msec | 1.8V; 180Hz; 60msec |
2 | M | ≤17 | 97 | Bilateral | Medtronic 3387 | 2.2V; 200Hz; 90msec | 2.2V; 200Hz; 90msec |
3 | M | ≤17 | 98 | bilateral | Medtronic 3387 | 2.5V; 180Hz; 90msec | 2.5V; 180Hz; 90msec |
4 | M | ≤17 | 89 | Bilateral | Medtronic 3387 | 5.0V; 210Hz; 90msec | 5.0V; 210Hz; 90msec |
5 | F | ≤17 | 93 | Bilateral | Medtronic 3387 | 2.0V; 200Hz; 90msec | 2.0V; 200Hz; 90msec |
6 | F | ≤17 | 85 | Bilateral | Medtronic 3387 | 4.0V; 180Hz; 90msec | 4.0V; 180Hz; 90msec |
7 | F | ≤17 | 100 | Bilateral | Medtronic 3387 | 3.5V; 180Hz; 90msec | 3.5V; 180Hz; 90msec |
8 | F | 31–52 | 100 | Bilateral | Medtronic 3387 | 5.0V; 200Hz; 100msec | 5.0V; 200Hz; 100msec |
9 | F | 18–30 | 100 | Bilateral | Medtronic 3387 | 2.3V; 200Hz; 120msec | 2.3V; 200Hz; 120msec |
10 | M | ≤17 | 85 | Bilateral | Medtronic 3387 | 2.0V; 130Hz; 60msec | 2.0V; 130Hz; 130msec |
11 | M | 18–30 | 100 | Bilateral | Medtronic 3387 | 3.0V; 180Hz; 90msec | 3.0V; 180Hz; 90msec |
12 | M | ≤17 | 89 | Bilateral | Medtronic 3387 | 5.5V; 185Hz; 130msec | 5.5V; 185Hz; 130msec |
13 | F | 18–30 | 47 | Bilateral | Medtronic 3387 | 7.0V; 250Hz; 120msec | 7.0V; 250Hz; 120msec |
14 | M | 18–30 | 100 | Bilateral | Medtronic 3387 | 5.0V; 210Hz; 130msec | 5.0V; 210Hz; 130msec |
15 | F | 18–30 | 90 | Bilateral | Medtronic 3387 | 3.5V; 180Hz; 90msec | 3.5V; 180Hz; 90msec |
16 | M | 18–30 | 100 | Bilateral | Medtronic 3387 | 5.0V; 200Hz; 100msec | 5.0V; 200Hz; 100msec |
17 | F | ≤17 | 100 | Bilateral | Medtronic 3387 | 3.5V; 180Hz; 90msec | 3.5V; 180Hz; 90msec |
18 | M | ≤17 | 97 | Bilateral | Medtronic 3387 | 4.5V; 180Hz; 90msec | 4.5V; 180Hz; 90msec |
19 | M | 31–52 | 88 | Bilateral | Medtronic 3389 | 3.0V; 180Hz; 90msec | 3.0V; 180Hz; 90msec |
20 | M | ≤17 | 91 | Bilateral | Medtronic 3389 | 3.2V; 180Hz; 90msec | 3.2V; 180Hz; 90msec |
21 | F | 18–30 | 18 | Bilateral | Medtronic 3389 | 3.8V; 180Hz; 90msec | 3.8V; 180Hz; 90msec |
22 | M | 31–52 | 89 | Bilateral | Medtronic 3389 | 3.5V; 180Hz; 90msec | 3.5V; 180Hz; 90msec |
23 | M | 31–52 | 2 | Bilateral | Medtronic 3389 | 4.5V; 150Hz; 247msec | 4.5V; 150Hz; 247msec |
24 | M | 18–30 | 57 | Unilateral | Medtronic 3389 | 0.3V; 150Hz; 450msec | Not applicable |
25 | M | 31–52 | 2 | Unilateral | Medtronic 3389 | 0.9V; 150Hz; 450msec | Not applicable |
26 | F | 31–52 | 65 | Bilateral | Medtronic 3389 | 0.1V; 60Hz; 180msec | 0.1V; 60Hz; 300msec |
27 | M | 18–30 | 59 | Bilateral | Medtronic 3389 | 0.7V; 150Hz; 330msec | 0.5V; 150Hz; 450msec |
28 | F | 31–52 | 48 | Unilateral | Medtronic 3389 | 0.1V; 150Hz; 450msec | Not applicable |
29 | M | 18–30 | 100 | Bilateral | Medtronic 3387 | 2.0V; 180Hz; 120msec | 2.0V; 180Hz; 120msec |
30 | M | 18–30 | 50 | Bilateral | Boston, Vercise | 1.0mA; 185Hz; 90msec | 1.0mA; 185Hz; 90msec |
31 | F | 18–30 | 50 | Bilateral | Boston, Vercise | 1.2mA; 113Hz; 120msec | 1.2mA; 113Hz; 120msec |
32 | M | 18–30 | 36 | Bilateral | Boston, Vercise | 1.0mA; 170Hz; 70msec | 1.0mA; 170Hz; 70msec |
33 | M | 18–30 | 58 | Bilateral | Boston, Vercise | 3mA; 185Hz; 60msec | 3mA; 185Hz; 60msec |
To preserve patients' anonymization, the diagnoses observed in this group are presented as the following list, from more to less frequent. Epilepsy, autism spectrum disorder, tuberous sclerosis, congenital rubella, intermittent explosive disorder, agenesia of the corpus callosum, schizophrenia, obsessive-compulsive disorder, West syndrome, Landau-Kleffner syndrome, Cri-du-chat syndrome, Lennox-Gastaut syndrome, Sotos syndrome, meningoencephalitis, perinatal hypoxia, periventricular leucomalacia, microcephaly, arteriovenous malformation. |
Functionally connected brain area | Peak coordinate | R | R2 | p-value |
---|---|---|---|---|
Periaqueductal Grey Matter | x=-1 y=-30 z=-10 | 0.725 | 0.525 | 1.86e-06 |
Vermis | x=1 y=-49 z=-12 | 0.702 | 0.493 | 5.21e-06 |
Medial Raphe nucleus | x=0 y=-25 z=-15 | 0.689 | 0.475 | 9.11e-06 |
Right Subst. Nigra, Subthalamic n., Zona Incerta | x=16 y=-14 z=-7 | 0.681 | 0.464 | 1.28e-05 |
Left Subst. Nigra, Subthalamic n., Zona Incerta | x=-14 y=-16 z=-7 | 0.673 | 0.453 | 1.77e-05 |
Left Claustrum | x=-30 y=14 z=-2 | 0.672 | 0.451 | 1.88e-05 |
Left Amygdala | x=-25 y=-8 z=-27 | 0.672 | 0.451 | 1.88e-05 |
Right Fusiform Gyrus | x=37 y=-10 z=-34 | 0.668 | 0.447 | 2.14e-05 |
Left Putamen | x=-33 y=-4 z=2 | 0.656 | 0.430 | 3.41e-05 |
Left Dorsal Anterior Cingulate Cortex | x=-2 y=25 z=22 | 0.654 | 0.428 | 3.65e-05 |
Right Superior Parietal Lobule | x=23 y=-62 z=63 | 0.652 | 0.425 | 3.95e-05 |
Left Transition Orbitofrontal Cortex- Insula | x=-24 y=11 z=-18 | 0.645 | 0.416 | 5.06e-05 |
Right Nucleus Accumbens | x=11 y=8 z=-7 | 0.645 | 0.416 | 5.07e-05 |
Right Amygdala | x=-22 y=-6 z=-26 | 0.645 | 0.416 | 5.14e-05 |
Left Anterior Insula | x=-39 y=18 z=-1 | 0.642 | 0.413 | 5.59e-05 |
Right Rostral Anterior Cingulate Cortex | x=9 y=40 z=-5 | 0.638 | 0.407 | 6.57e-05 |
Right Bed Nucleus Of The Stria Terminallis | x=7 y=8 z=-5 | 0.638 | 0.407 | 6.57e-05 |
Left Bed Nucleus Of The Stria Terminallis | x=-6 y=8 z=-5 | 0.638 | 0.407 | 6.57e-05 |
Left Nucleus Acuumbens | x=-11 y=8 z=-7 | 0.638 | 0.407 | 6.57e-05 |
Right Transition Orbitofrontal Cortex- Insula | x=25 y=10 z=-15 | 0.638 | 0.407 | 6.57e-05 |
Right Hypothalamus | x=5 y=-3 z=-11 | 0.631 | 0.398 | 8.25e-05 |
Left Fusiform Gyrus | x=-34 y=-12 z=-33 | 0.629 | 0.396 | 8.72e-05 |
Left Hypothalamus | x=-4 y=-3 z=-11 | 0.621 | 0.386 | 1.13e-04 |
Matrix of the correlations between estimated symptom improvement (i.e. linear model of age and functional connectivity of the two areas) and the measured improvement.